Dr Federica Begalli

Profile

ORCID iD: 0000-0002-7478-0252

LinkedIn 

Federica obtained her BSc in Biotechnology and her MSc cum laude in Medical, Molecular and Cellular Biotechnology from La Sapienza University of Rome. She obtained her PhD in Biomedical Technologies in Clinical Medicine from La Sapienza University of Rome as part of a joint project with Imperial College London.

Federica held her first post-doctoral position at Imperial College London, where she secured funding for her own project with Bloodwise and she started teaching in the MSc Program in Molecular Medicine. During her PhD and her first post-doc, Federica developed a passion for translational science. Following this led her to a second post-doc in Marta Korbonits’ laboratory at Queen Mary University of London, where she started a collaboration with ONO Pharmaceutical and secured two rounds of funding for their collaborative projects. At QMUL, Federica also started lecturing and teaching PBLs as part of the BSc in Pharmacology and Innovative Therapeutics, as well as the MBBS, and she obtained the Fellowship of Higher Education Academy in 2020.

Since January 2023, Federica is a Lecturer in Endocrinology and Education Lead for the Centre for Endocrinology. She co-leads two modules in Endocrine Physiology and Biochemistry.

Federica is member of the British Society for Endocrinology, the European Society of Endocrinology, European Neuroendocrine Association.

Research

Federica’s main research interest is to unveil the molecular mechanisms behind tumour development and progression and use her findings in clinical applications. Her research focuses on Non-Functioning Pituitary Neuroendocrine Tumours, where she is developing novel biomarkers as well as therapeutic strategies. She works closely with clinicians and pharmaceutical companies to achieve these goals.

Publications

• Rai A, Begalli F, Barry S et al. . CDC42: a potential therapeutic target of clinically non-functioning pituitary neuroendocrine tumours.

  
  

  DOI: 10.1530/endoabs.94.oc3.1

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/92759
• Sanpawithayakul K, Mistry A, Rai A et al. . Hindering the progression of cardiac fibrosis in acromegaly - the role of somatostatin receptor ligands.

  
  

  DOI: 10.1530/endoabs.94.p363

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/92003
• Begalli F, Botta J, Collier D et al. (2022). PMON170 Treating human primary non-functioning pituitary adenoma cells with cabergoline.

  
  

  DOI: 10.1210/jendso/bvac150.1140

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/83875
• Benjamin LP, Suleyman O, Begalli F et al. . Aberrant cyclic GMP-AMP synthase stimulator of interferon genes signalling in an AIP mutant cell line.

  
  

  DOI: 10.1530/endoabs.86.p97

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/84182
• Begalli F, Komagata T, Suleyman O et al. . Cabergoline treatment in human primary non-functioning pituitary adenomas.

  
  

  DOI: 10.1530/endoabs.77.p212

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/75749
• Capece D, Verzella D, Begalli F et al. (2021). Extracellular Flux Analysis to Investigate the Impact of NF-κB on Mitochondrial RespirationMitochondrial respiration in Colorectal Carcinoma (CRC).

  
  

  DOI: 10.1007/978-1-0716-1669-7_18

  
  

  QMRO:
• Capece D, D'Andrea D, Begalli F et al. (2021). Enhanced triacylglycerol catabolism by Carboxylesterase 1 promotes aggressive colorectal carcinoma.

  
  

  DOI: 10.1172/jci137845

  
  

  QMRO:
• Rajpoot S, Bennett J, Franzoso G et al. (2020). Reprogramming immunosuppressive tumour-associated dendritic cells with GADD45β inhibitors.

  
  

  DOI: 10.7861/clinmed.20-2-s116

  
  

  QMRO:
• Mistry A, Solomou A, Vignola ML et al. . Investigating the role of AIP in pituitary tumourigenesis.

  
  

  DOI: 10.1530/endoabs.65.oc2.2

  
  

  QMRO:
• Bollington M, Mistry A, Solomou A et al. . Transcriptomic analyses reveal deregulation of focal adhesion pathway in Aip KO mice and AIP mutation positive human tumours.

  
  

  DOI: 10.1530/endoabs.65.op6.2

  
  

  QMRO:

Collaborators

Internal

• Prof Márta Korbonits
• Dr Carles Gaston-Massuet
• Dr Jack Williams
• Giulia Mastroianni

External

• Prof Peter McCormick
• Mr Pinaki Dutta
• Dr Ashutosh Rai

Teaching

Federica is Education Lead for the Department for Endocrinology.

She co-leads two modules in “Endocrinology Physiology and Biochemistry”, BMD311 in London and SNU303 in Nanchang, China. Furthermore, she contributes to other teaching modules in the School of Medicine and Dentistry, in the BSc in Pharmacology and Innovative Therapeutics, and in the Nanchang Joint Programme. 

Federica is a Fellow of the Higher Education Academy since 2020. 

She has been supervising and mentoring students as well as research staff since 2011, for a total of: 

• 6 BSc students (primary supervisor)
• 1 BMedSci student
• 3 MSc students
• 1 MRes student
• 4 PhD students
• 1 Laboratory Technician
• 2 Post-doc Researchers

Disclosures

• In 2021 – 2023 Dr Federica Begalli has received a project grant funding from ONO Pharmaceutical Co., Ltd.
• In 2020 – 2021 Dr Federica Begalli has received a project grant funding from ONO Pharmaceutical Co., Ltd.